[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Kastritis E, Dimopoulos MA, Antoniou N, Deliveliotis C, Chrisofos M, Skolarikos A, Gika D, Bamias A: The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res; 2006 Sep-Oct;26(5B):3865-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy.
  • BACKGROUND: There is limited information about the benefit from systemic chemotherapy in non-pure Transitional Cell Carcinomas (TCCs) of the urothelial tract.
  • In this study the efficacy of platinum-based chemotherapy in patients with pure squamous or mixed carcinomas was retrospectively analysed and compared with that in pure TCCs.
  • PATIENTS AND METHODS: Analysis included 446 consecutive patients treated with platinum-based chemotherapy for advanced or metastatic urothelial cancer.
  • There were 389 (87%) patients with pure TCC, 15 (3.5%) with pure Squamous Cell Carcinomas (SCC) and 42 (9.5%) patients had mixed histology (TCC+SCC) tumors.
  • CONCLUSION: Non-transitional histology does not predict for an inferior survival after platinum-based chemotherapy for advanced urothelial carcinoma.
  • Well-known prognostic factors in transitional cell carcinomas were also associated with prognosis in mixed carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094415.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


2. Raghavan D: Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer; 2003 Apr 15;97(8 Suppl):2050-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the chemotherapy of metastatic cancer of the urinary tract.
  • Cytotoxic chemotherapy has an evolving role in the management of metastatic cancer of the bladder and urinary tract.
  • The most responsive of these tumors are transitional cell carcinomas.
  • Standard single agents (e.g., methotrexate, doxorubicin, mitomycin, ifosfamide, vinblastine, and cisplatin) have produced objective response rates of 15-25% and combination chemotherapy has resulted in objective regression in 40-75% of cases.
  • Traditional cytotoxic regimens have been ineffective in the management of adenocarcinoma and squamous cell carcinoma of the bladder.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / secondary. Humans. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society
  • (PMID = 12673696.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


3. Washino S, Terauchi F, Matsuzaki A, Kobayashi Y: [Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia]. Nihon Hinyokika Gakkai Zasshi; 2008 Sep;99(6):703-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia].
  • We report two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia.
  • Case 1; a 54 year old female with primary squamous cell carcinoma (SCC) of right ureter showed marked hypercalcemia and leukocytosis.
  • Although chemotherapy of cisplatin and 5-fluorouracil with radiotherapy was effective, thereafter recurrence was occurred in renal pelvis, and the patient died 17 months after the initiation of therapy.
  • Although the patient was administered UFT with palliative radiotherapy to the anterior mediastinum, he died 2 months after the initiation of therapy.
  • To our knowledge, the case 1 is the third case that of the high levels of serum PTHrP and G-CSF simultaneously in squamous cell carcinoma of upper urinary tract.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Hypercalcemia / etiology. Kidney Neoplasms / complications. Kidney Pelvis. Ureteral Neoplasms / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fatal Outcome. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / biosynthesis. Granulocyte Colony-Stimulating Factor / blood. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Parathyroid Hormone-Related Protein / biosynthesis. Parathyroid Hormone-Related Protein / blood. Radiotherapy. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939454.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; 1-UFT protocol
  •  go-up   go-down


Advertisement
4. Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R: Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med; 2009 Nov;50(11):1828-36
Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-based therapy.
  • The aim of the present first-in-humans (89)Zr immuno-PET study was to assess safety, biodistribution, radiation dose, and quantification of the (89)Zr-labeled chimeric monoclonal antibody (cmAb) U36 in patients with head and neck squamous cell carcinoma (HNSCC).
  • Uptake levels and residence times in blood, tumors, and organs of interest were derived from quantitative immuno-PET studies, and absorbed doses were calculated using OLINDA/EXM 1.0.
  • The red marrow dose was calculated using the residence time for blood.
  • Measured excretion via the urinary tract was less than 3% during the first 72 h.
  • CONCLUSION: (89)Zr immuno-PET can be safely used to quantitatively assess biodistribution, uptake, organ residence times, and radiation dose, justifying its further clinical exploitation in the detection of tumors and planning of mAb-based therapy.
  • [MeSH-minor] Aged. Bone Marrow / radiation effects. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radionuclide imaging. Clinical Trials as Topic. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Isotope Labeling. Male. Middle Aged. Positron-Emission Tomography. Radiation Dosage. Radioisotopes. Radiometry. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837762.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Recombinant Fusion Proteins; C6V6S92N3C / Zirconium
  •  go-up   go-down


5. Yoshinaga A, Hayashi T, Ishii N, Ohno R, Terao T, Kamata S, Watanabe T, Yamada T: [Vesicorectal fistula caused by pelvic metastasis of penile cancer: a case report]. Hinyokika Kiyo; 2005 Jan;51(1):53-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor biopsy revealed squamous cell carcinoma.
  • Although he was given radiation therapy and subcutaneous injection therapy of bleomycin, viable cancer cells remained.
  • Then he was given combination chemotherapy of bleomycin and cisplatin, and paint therapy of bleomycin ointment.
  • Local recurrence with a cauliflower-like tumor occurred five years after the chemotherapy.
  • Computerized tomography of pelvis demonstrated a mass 3 cm in diameter in the anterior portion of anal and cystogram demonstrated a vesicorectal fistula.
  • Then we inserted a urethral catheter, which resulted in obstruction of fistula by its balloon, and we made a cystostomy for securing urinary tract.
  • Pathological examination of tissue around the fistula revealed squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Pelvic Neoplasms / secondary. Penile Neoplasms / pathology. Rectal Fistula / etiology. Urinary Bladder Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732344.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Kietpeerakool C, Lattiwongsakorn W, Srisomboon J: Incidence and predictors of febrile morbidity after radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer patients. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):213-6
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical variables including the age at diagnosis, menopausal status, body mass index, previous cervical conization, tumor size, preoperative chemotherapy, preoperative anemia, operative time, and estimated blood loss were analyzed for prediction of postoperative febrile morbidity.
  • The most common histology was squamous cell carcinoma (69.2%).
  • Febrile morbidity was noted in 94 women (26.3%, 95% CI= 21.8-31.2) in whom 25 (7.0%) had urinary tract infection (19), abdominal wound infection (4), and vaginal cuff infection (2), respectively.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Fever / etiology. Hysterectomy / adverse effects. Lymph Node Excision / adverse effects. Postoperative Complications. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Blood Loss, Surgical. Female. Humans. Incidence. Middle Aged. Risk Factors. Surgical Wound Infection / epidemiology. Surgical Wound Infection / etiology. Surgical Wound Infection / prevention & control. Treatment Outcome. Urinary Tract Infections / epidemiology. Urinary Tract Infections / etiology. Urinary Tract Infections / prevention & control


7. Tamas EF, Nielsen ME, Schoenberg MP, Epstein JI: Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol; 2007 Aug;20(8):828-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases.
  • We studied 28 cases of lymphoepithelioma-like carcinoma of the bladder, one case in the renal pelvis, and one in the urethra.
  • Seventeen cases (56.7%) were pure with the remaining mixed with other patterns of carcinoma, including invasive urothelial carcinoma (n=10), invasive adenocarcinoma (n=3), and squamous cell carcinoma (n=2).
  • The surface demonstrated carcinoma in situ (CIS) in six cases, noninvasive high-grade papillary urothelial carcinoma in three cases, and in situ adenocarcinoma in one case.
  • Treatment consisted of radical cystectomy in 13/30 cases (43%); partial cystectomy in 4/30 cases (13%); nephrectomy in one case (3%), and transurethral resection often followed by radiation or chemotherapy in 12/30 (40%) cases.
  • Lymphoepithelioma-like carcinoma, whether in pure or mixed form, has a similar prognosis to ordinary urothelial carcinoma when treated by cystectomy.
  • Of the three pure cases treated by chemotherapy, two were free of disease at 4 and 65 months and the third had recurrent disease at 17 months.
  • Given the association of lymphoepithelioma-like carcinoma with urothelial carcinoma in 47% of our cases and its propensity for multifocality, partial cystectomy would typically be ill advised for lymphoepithelioma-like carcinoma.
  • [MeSH-major] Carcinoma / pathology. Urologic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Disease-Free Survival. Epithelial Cells / pathology. Female. Follow-Up Studies. Humans. Lymphocytes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541442.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. De Santis M, Bachner M: New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Curr Opin Urol; 2007 Sep;17(5):363-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
  • PURPOSE OF REVIEW: To review the systemic treatment, patient selection and treatment outcome of transitional cell carcinoma of the urinary bladder, squamous cell carcinoma and adenocarcinoma, focusing on advances and findings within the last year.
  • RECENT FINDINGS: Cisplatin-based chemotherapy is considered to be the standard treatment for transitional cell carcinoma.
  • In recent updates of randomized trials, patients with favorable prognostic factors were shown to have a chance of long-term disease-free survival even after chemotherapy for metastatic disease.
  • Patient selection for cisplatin, newer drugs or alternative combinations is crucial.
  • New genetic markers like excision repair cross-complementing 1 expression were developed and tested for this purpose.
  • Adequate evaluation of renal function plays an important role for treatment selection, especially in the elderly population.
  • Only few data are available on the systemic treatment of squamous cell carcinoma and adenocarcinoma.
  • Complete resection seems to be more important than chemotherapy in the rare cases of adenocarcinoma of the urinary tract.
  • SUMMARY: In locally advanced and metastatic disease patient- and tumor-related prognostic factors and predictive factors for response to treatment will guide treatment decisions in the future.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Age Factors. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Humans. Neoplasm Metastasis. Patient Selection. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762632.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 58
  •  go-up   go-down


9. Riadh BS, El Atat R, Sfaxi M, Derouiche A, Kourda N, Chebil M: Clinical presentation and outcome of bladder schistosoma-unrelated squamous cell carcinoma: report on 33 consecutive cases. Clin Genitourin Cancer; 2007 Sep;5(6):409-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation and outcome of bladder schistosoma-unrelated squamous cell carcinoma: report on 33 consecutive cases.
  • BACKGROUND: Pure squamous cell carcinoma (SCC) is a rare entity in Western countries.
  • The management of SCC still remains similar to that of transitional carcinoma, although it is a different entity.
  • A retrospective review is helpful in understanding the epidemiologic aspects, pathogenesis, and treatment and prognosis of schistosoma-unrelated SCC.
  • Eleven patients (34%) had a bladder stone with recurrent urinary tract infection; they had been treated since age 6-17 years.
  • Twenty-one patients underwent radical cystectomy, followed by chemotherapy in 2 cases.
  • CONCLUSION: The unrelated SCC has an unfavorable prognosis, mostly caused by the locally advanced disease at the time of presentation.
  • The transfer of novel chemotherapy regimens and preoperative radiation therapy should be considered because pelvic recurrences are the leading cause of progression in SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / parasitology. Schistosoma haematobium / isolation & purification. Schistosomiasis haematobia / parasitology. Urinary Bladder Neoplasms / parasitology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Child. Cystectomy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Urinary Bladder Calculi / etiology. Urinary Bladder Calculi / surgery. Urinary Tract Infections / etiology. Urinary Tract Infections / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956717.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Serretta V, Pomara G, Piazza F, Gange E: Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol; 2000 Jan;37(1):85-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases.
  • INTRODUCTION: Pure squamous carcinoma (SCC) is a rare entity in western regions.
  • The management of SCC still remains similar to that of transitional carcinoma, although it is a different entity.
  • Involvement of prostatic urethra and upper urinary tract was evident in 9 (47.3%) and 5 patients (26.3%), respectively.
  • Four patients were submitted to neoadjuvant chemotherapy and 1 to presurgical radiotherapy without any objective response.
  • Adjuvant chemotherapy was performed in 3 patients.
  • CONCLUSIONS: Invasion of the upper urinary tract and prostatic urethra seems more common in SCC than in transitional cell carcinoma.
  • Preoperative radiotherapy should be considered since pelvic recurrences are the leading cause of progression in squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671791.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


11. Kim DS, Lee YH, Cho KS, Cho NH, Chung BH, Hong SJ: Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology; 2010 Feb;75(2):328-32
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma.
  • OBJECTIVES: To investigate the prognostic significance of lymphovascular invasion (LVI) in patients with localized upper urinary tract transitional cell carcinoma (UUT-TCC) after radical nephroureterectomy.
  • LVI was related to higher pT stage, high tumor grade, sessile architecture, and squamous differentiation.
  • On univariate analysis, tumor architecture, squamous differentiation, LVI, tumor grade, and pT stage influenced disease-specific survival.
  • LVI and pT stage would be helpful for selecting patients who are appropriate for postoperative adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery. Vascular Neoplasms / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2010 Feb;75(2):332-3 [20152482.001]
  • [CommentIn] Urology. 2010 Feb;75(2):333 [20152483.001]
  • (PMID = 20018349.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF: Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology; 2006 Mar;67(3):518-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper urinary tract tumors with nontransitional histology: a single-center experience.
  • OBJECTIVES: To review our experience with patients with upper urinary tract tumors of nonurothelial origin.
  • Upper urinary tract tumors of nonurothelial origin are uncommon entities.
  • Anderson Cancer Center from 1990 to 2004 to identify patients with primary nonurothelial tumors of the upper urinary tract.
  • We reviewed the patient records to collect data on tumor subtype, treatment, recurrence, and survival.
  • RESULTS: Sixteen patients (1.9% of our database of patients with upper urinary tract tumors) were identified; 12 had squamous cell carcinoma, 2 had adenocarcinoma, 1 had sarcomatoid carcinoma, and 1 had small cell carcinoma.
  • Of the 16 patients, 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy.
  • Ten patients received adjuvant chemotherapy.
  • The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%.
  • The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively.
  • Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527570.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79449; United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Nabi G, Ansari MS, Singh I, Sharma MC, Dogra PN: Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity. Report of 2 cases and review of literature. Urol Int; 2001;66(4):216-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity. Report of 2 cases and review of literature.
  • Primary squamous cell carcinoma of the prostate is an uncommon clinicopathological entity.
  • It differs from more common adenocarcinomas in its cell of origin, biological behavior, therapeutic response to the usual hormonal manipulation and prognosis.
  • The review shows that squamous cell carcinoma is biologically more aggressive than adenocarcinoma.
  • Despite the agreement on its uniqueness, a controversy exists on the exact histopathogenesis, diagnostic criteria and modality of treatment.
  • We report on 2 patients with primary squamous cell carcinoma of the prostate.
  • One patient presented with lower urinary tract symptoms with a hard nodular prostate on digital rectal examination, and the other with acute urinary retention on normal digital rectal examination.
  • Palliative transurethral resection of the prostate with chemotherapy (Adriamycin based) was given in both the cases.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11385309.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


14. Mayer EK, Beckley I, Winkler MH: Lymphoepithelioma-like carcinoma of the urinary bladder--diagnostic and clinical implications. Nat Clin Pract Urol; 2007 Mar;4(3):167-71
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the urinary bladder--diagnostic and clinical implications.
  • INVESTIGATIONS: Physical examination, ultrasound of the urinary tract, and intravenous urography were all unremarkable.
  • DIAGNOSIS: Histologically, the tumor was described as a G3 pT1 transitional cell carcinoma of the bladder.
  • MANAGEMENT: Following the resection of a solitary recurrence 6 weeks after the initial tumor resection, the patient underwent a standard course of intravesical bacillus Calmette-Guérin therapy.
  • Histologically, this tumor was described as a lymphoepithelioma-like carcinoma, of at least grade G3pT1.
  • The patient underwent radical cystoprostatectomy with ileal conduit formation; no adjuvant systemic chemotherapy was given in light of complete tumor resection.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Cystectomy / methods. Prostatectomy / methods. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Urography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347662.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Tazi K, Moudouni S, Karmouni T, Koutani A, Hachimi M, Lakrissa A: [Epidermoid carcinoma of the male urethra]. Prog Urol; 2000 Sep;10(4):600-2
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinoma of the male urethra].
  • Squamous cell carcinoma of the male urethra is exceptional, as all urethral tumours represent less than 1% of urinary tract tumours.
  • Treatment depends on the stage and site of the lesion, but the prognosis remains very poor despite aggressive treatment, including mutilating resection surgery with or without associated radiotherapy.
  • However, the current hope for patients with squamous cell carcinoma of the urethra resides in radiotherapy-chemotherapy combination protocols based on the results obtained in squamous cell cancers of the oesophagus and anus.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Urethral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064906.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 15
  •  go-up   go-down


16. Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, Itoh N, Tsukamoto T: Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology; 2000 May;55(5):663-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for the development of bladder cancer after upper tract urothelial cancer.
  • The intravesical disease-free rate after upper tract urothelial cancer was 65% (rate of disease recurrence in bladder 35%) at 5 years by the Kaplan-Meier method.
  • The extent (multifocality) of the upper urinary cancer (P = 0.0038) and pathologic stage (P = 0.0409) independently influenced intravesical recurrence.
  • Age, sex, adjuvant chemotherapy, configuration of the primary tumor, primary cancer size, and pathologic grade did not affect recurrence.
  • The rate of stage progression also was not influenced by the extent of the disease in the upper urinary tract.
  • CONCLUSIONS: The extent and pathologic stage of cancer in the upper urinary tract were significant and independent factors for initial intravesical recurrence of cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792075.001).
  • [ISSN] 0090-4295
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD, EORTC Genito-Urinary Tract Cancer Group: A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol; 2008 Jul;19(7):1304-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
  • There were eight responses (two complete response and six partial response) (30.8%, 80% confidence interval 18.8% to 45.1%): three patients undergoing histological verification after chemotherapy had no evidence of malignancy.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417462.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-34; United States / NCI NIH HHS / CA / 5U10 CA11488-35; United States / NCI NIH HHS / CA / 5U10 CA11488-36; United States / NCI NIH HHS / CA / 5U10 CA11488-37
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Chaigneau L, Villanueva C, Thierry-Vuillemin A, Legat-Fagnoni C, N'Guyen T, Maurina T, Lorgis V, Pivot X: [Pemetrexed development in oncology]. Bull Cancer; 2007;94 Spec No Actualites:S142-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pemetrexed disodium (Alimta), LY231514) is the first antifolate able to inhibit at the same time the synthesis of purins and pyrimidins.
  • Many therapeutic tests were carried out in clinical situations where the methotrexate and the fluorouracil had been the proof of their effectiveness.
  • The two randomized studies carried out in the malignant pleural mesothelioma and the non small cell lung cancer made it possible to establish its utility and to record the pemetrexed in these clinical situations.
  • Others axes of development remain possible, but the results are stanby or to confirm as in squamous-cell cancer in the head and neck and breast, digestive or urinary tracts cancer.
  • In all the cases, the optimization of the pemetrexed in terms of amount/methods of administration and associations possible because of its profile of tolerance makes of it a molecule of chemotherapy with a future.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / drug therapy. Digestive System Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Female. Humans. Lung Neoplasms / drug therapy. Male. Mesothelioma / drug therapy. Pemetrexed. Pleural Neoplasms / drug therapy. Respiratory Tract Neoplasms / drug therapy. Urogenital Neoplasms / drug therapy

  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845985.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 58
  •  go-up   go-down


19. Kokka F, Vorgias G, Tserkezoglou A, Tsiaousi I, Hadjieleftheriou G, Andriotis M, Akrivos T, Fotiou S, Apostolikas N: Preoperative work-up of early cervical cancer (stages Ib-IIa). Eur J Gynaecol Oncol; 2003;24(2):175-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS: We retrospectively reviewed the medical records of 309 patients with previously untreated early cervical carcinoma who completed pretreatment evaluation at "St. Savas" Cancer Hospital of Athens and "Metaxas" Memorial Hospital of Peireas between January 1986 and September 1, 2000.
  • Histologic type was squamous (267 pts.
  • Patients with early stage cervical carcinoma were treated with Wertheim-Meigs radical hysterectomy and pelvic lymphadenectomy, while those with advanced stage cervical carcinoma were treated with radiotherapy and chemotherapy.
  • RESULTS: In urinary tract investigation, CT showed a sensitivity of 100% and a specificity of 99.67%.
  • In gastrointestinal tract investigation CT showed a sensitivity of 50% and a specificity of 99.67%.
  • CONCLUSION: In our series of patients with early stage cervical carcinoma, imaging and endoscopic tests added limited information over pelvic examination and altered in four cases (1.29%) the choice of the appropriate treatment modality.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Preoperative Care / methods. Urologic Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Colonoscopy. Cystoscopy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701973.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. van der Kamp R, Nienhuis JE, Rosekrans PA, Dees A: [Two patients with emphysematous pyelonephritis]. Ned Tijdschr Geneeskd; 2000 Apr 8;144(15):713-6
MedlinePlus Health Information. consumer health - Emphysema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The man had a difficult recovery after treatment with antibiotics and percutaneous drainage.
  • In the woman, a calculus obstructed the pyelo-ureteral passage; the resected kidney contained a squamous cell carcinoma.
  • She was operated, received chemotherapy and recovered.
  • Percutaneous drainage and, if necessary, nephrectomy are paramount in the treatment.
  • The condition is observed mostly in patients with diabetes mellitus or obstruction of the urinary tract.
  • [MeSH-major] Emphysema. Escherichia coli Infections. Pyelonephritis / therapy
  • [MeSH-minor] Adult. Anti-Bacterial Agents. Drug Therapy, Combination / therapeutic use. Escherichia coli / isolation & purification. Female. Humans. Hydronephrosis / etiology. Male. Middle Aged. Nephrectomy. Nephrostomy, Percutaneous. Treatment Outcome. Ureteral Calculi / complications. Ureteral Obstruction / complications

  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10778721.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 10
  •  go-up   go-down


21. Stranzl H, Gabor S, Mayer R, Prettenhofer U, Wurzinger G, Hackl A: Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries. Strahlenther Onkol; 2002 Aug;178(8):442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
  • PATIENTS AND METHOD: Between 1991 and 1998, eleven patients (female n = 3, male n = 8; age: median 66 years, range 44-81 years) underwent intraluminal HDR brachytherapy for histologically confirmed endobronchial metastases from non-pulmonary primary tumors of various sites like urogenital tract (n = 5), gastrointestinal tract (n = 3), ear/nose/throat (n = 2) and breast (n = 1).
  • The median time between diagnosis of the primary non-bronchogenic tumor and histopathological diagnosis of the endobronchial metastases was 39 months, range 1-99 months.
  • A total dose of 15-20 Gy was delivered in three to four fractions of 5-6 Gy once a week.
  • No palliative chemotherapy was added.
  • Treatment was judged unsuccessful in three (27%) patients.
  • The applied treatment is a safe, effective and well tolerated palliative procedure leading to an improved patient quality of life.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Breast Neoplasms. Carcinoma, Renal Cell / radiotherapy. Carcinoma, Renal Cell / secondary. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / secondary. Dose Fractionation. Female. Follow-Up Studies. Humans. Kidney Neoplasms. Male. Middle Aged. Palliative Care. Prostatic Neoplasms. Radiotherapy Dosage. Rectal Neoplasms. Sigmoid Neoplasms. Time Factors. Tongue Neoplasms. Tonsillar Neoplasms. Urinary Bladder Neoplasms. Uterine Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12240550.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


22. Bellmunt J, Cos J, Clèries R, Pérez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J: Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest; 2002;20(5-6):673-85
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
  • To evaluate the clinical value of the concurrent use of methotrexate administered immediately before paclitaxel, we investigated the efficacy and toxicity of this two-drug combination administered as palliative second line therapy in patients with advanced urothelial cancer.
  • The design of the schedule and sequence used was based on our previous preclinical data from a comparative study on sequential combinations of paclitaxel and methotrexate in a human bladder cancer cell line.
  • Twenty patients with advanced transitional cell carcinoma of the urinary tract previously treated with platinum-based therapy, with adequate renal function and a performance status > or = 60 were considered eligible.
  • They received therapy with methotrexate 30 mg/m2 administered as an intravenous bolus, followed immediately by paclitaxel 175 mg/m2 given as a 3-hr infusion, both on day 1 every 21 days.
  • Therapy was given on a compassionate-use basis until either disease progression was documented or the patient became intolerant to therapy.
  • Twenty patients with metastatic (16 patients) or locally advanced disease (four patients) received a median of three cycles of therapy.
  • Three patients developed grade 3-4 neutropenia, one patient had grade 3 anemia, four patients had grade 2-3 sensory neuropathy, and three patients had myalgias.
  • Eighteen patients developed alopecia.
  • In conclusion, the combination of methotrexate and paclitaxel at this dose and sequence is feasible and active as a palliative therapy in patients with advanced urothelial cancer previously treated with platinum-based therapies.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Kidney Neoplasms / drug therapy. Palliative Care. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Anemia / chemically induced. Drug Administration Schedule. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Peripheral Nervous System Diseases / chemically induced. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Invest. 2002;20(5-6):855-6 [12197246.001]
  • (PMID = 12197223.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement